Protective effect of budesonide/formoterol compared with formoterol, salbutamol and placebo on repeated provocations with inhaled AMP in patients with asthma: a randomised, double-blind, cross-over study by René Aalbers et al.
Aalbers et al. Respiratory Research 2010, 11:66
http://respiratory-research.com/content/11/1/66
Open AccessR E S E A R C HResearchProtective effect of budesonide/formoterol 
compared with formoterol, salbutamol and 
placebo on repeated provocations with inhaled 
AMP in patients with asthma: a randomised, 
double-blind, cross-over study
René Aalbers1, Martin Boorsma2, Hanneke J van der Woude1 and René E Jonkers*3
Abstract
Background: The budesonide/formoterol combination is successfully used for fast relief of asthma symptoms in 
addition to its use as maintenance therapy. The temporarily increased corticosteroid dose during increasing inhaler use 
for symptom relief is likely to suppress any temporary increase in airway inflammation and may mitigate or prevent 
asthma exacerbations. The relative contribution of the budesonide and formoterol components to the improved 
asthma control is unclear.
Methods: The acute protective effect of inhaled budesonide was tested in a model of temporarily increased airway 
inflammation with repeated indirect airway challenges, mimicking an acute asthma exacerbation. A randomised, 
double-blind, cross-over study design was used. Asthmatic patients (n = 17, mean FEV1 95% of predicted) who 
previously demonstrated a ≥30% fall in forced expiratory volume in 1 second (FEV1) after inhaling adenosine 5'-
monophosphate (AMP), were challenged on four consecutive test days, with the same dose of AMP (at 09:00, 12:00 and 
16:00 hours). Within 1 minute of the maximal AMP-induced bronchoconstriction at 09:00 hours, the patients inhaled 
one dose of either budesonide/formoterol (160/4.5 μg), formoterol (4.5 μg), salbutamol (2 × 100 μg) or placebo. The 
protective effects of the randomised treatments were assessed by serial lung function measurements over the test day.
Results: In the AMP provocations at 3 and 7 hours after inhalation, the budesonide/formoterol combination provided 
a greater protective effect against AMP-induced bronchoconstriction compared with formoterol alone, salbutamol and 
placebo. In addition all three active treatments significantly increased FEV1 within 3 minutes of administration, at a time 
when inhaled AMP had induced the 30% fall in FEV1.
Conclusions: A single dose of budesonide/formoterol provided a greater protective effect against inhaled AMP-
induced bronchoconstriction than formoterol alone, both at 3 and at 7 hours after inhalation. The acute protection 
against subsequent bronchoconstrictor stimuli such as inhaled AMP and the rapid reversal of airway obstruction 
supports the use of budesonide/formoterol for both relief and prevention in the treatment of asthma.
Trial Registration: ClinicalTrials.gov number NCT00272753
Background
The short-acting β2-agonist salbutamol is widely used as
first-line treatment in the management of acute broncho-
constriction in asthma because of its fast onset of action
[1]. The long-acting β2-agonist formoterol has an onset of
effect that is comparable with that of salbutamol [2] and,
when used as reliever therapy, has proven to be superior
to terbutaline and salbutamol in improving asthma con-
trol and preventing asthma exacerbations [3-5]. The com-
bination of budesonide and formoterol in one inhaler,
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compared with a similar or higher dose of an inhaled cor-
ticosteroid (ICS) alone [6,7]. Furthermore, budesonide/
formoterol is also effective in situations of acute and
severe bronchoconstriction [8,9], indicating that it is
effective as a reliever therapy. Clinical studies have sub-
stantiated that budesonide/formoterol can be used as
both maintenance and reliever therapy, resulting in
improved asthma control and an additional reduction in
exacerbation frequency compared with maintenance
therapy plus a separate bronchodilator for relief [10-14].
The effectiveness of this novel treatment regimen, where
patients use budesonide/formoterol as their only medica-
tion, is thought to be the result of a rapid increase in ICS
dose at the earliest onset of symptoms [15].
A single dose of an ICS is thought to have limited bron-
chodilating effects and some immediate bronchoprotec-
tive effect [16,17]. In addition, an ICS has a
vasoconstrictor effect in the airway mucosa, which can be
measured within hours of administration [18].
Inhaled adenosine 5'-monophosphate (AMP) induces
rapid degranulation of airway mast cells leading to bron-
choconstriction and airway oedema and is, therefore,
considered to mimic acute asthma attacks caused by
allergen, cold air or exercise [19,20]. Bronchodilators can
reverse AMP-induced bronchoconstriction and can also
immediately protect against AMP-induced bronchocon-
striction [21-23]. Long-term ICS treatment has a protec-
tive effect on bronchial hyperresponsiveness, as
measured with inhaled AMP [24], but an ICS has also a
small immediate protective effect against AMP induced
bronchoconstriction, which lasts for several hours
[25,26].
In daily life, patients with asthma can be repeatedly
exposed to allergic and non-specific triggers resulting in
airway constriction and asthma attacks. The present
study was, therefore, designed to assess the protective
effect of a single low dose of budesonide/formoterol with
that of β2-agonist treatment only (formoterol or salbuta-




Outpatients were included if they were: aged between 18
and 55 years with a diagnosis of asthma [1], had an FEV1
of >60% of predicted (26), used an inhaled corticosteroid
in a dose of ≥ 100 μg daily, a provocative concentration of
AMP causing a 20% fall in FEV1 (PC20-AMP) ≤160 mg/
ml, and a demonstrated fall in FEV1 of >30% upon contin-
uation of the AMP provocation. Patients had to be able to
use and inhale correctly through Turbuhaler® and a pres-
surised metered-dose inhaler (pMDI) connected to a
large volume spacer device (Volumatic®); inhalation tech-
nique was practised until correct.
Patients were excluded from the study if, within 6
weeks prior to enrolment, they had used systemic corti-
costeroids, had experienced an asthma exacerbation or
changed their ICS dose. Female patients who were preg-
nant, planning pregnancy, breastfeeding or not using an
adequate method of contraception were also excluded.
Patients were asked to avoid strenuous exercise, smoking
and consumption of caffeine-containing beverages in the
morning prior to the test days and throughout each of the
test days. The study was performed in accordance with
the ethical principles that have their origin in the Decla-
ration of Helsinki and in accordance with Good Clinical
Practice guidelines. The study was approved by the Medi-
cal Ethics Committees of both hospitals (Medical Ethics
Committee Martini Ziekenhuis, reference number 2003-
44 and Medical Ethics Committee Academic Medical
Centre Amsterdam, reference number MEC 05/074.
Written informed consent was obtained from all patients
prior to their enrolment.
Study design
This randomised, double-blind, double-dummy, placebo-
controlled, cross-over study (study code BN-00S-0022,
NIH ClinicalTrials.gov trial data base number
NCT00272753) was conducted at two centres. The study
comprised an initial enrolment visit at the start of the
run-in period, a short visit at the end of the run-in period
and four test days that were all separated by 5-14 days.
The assessments on each test day are graphically shown
in Figure 1.
At enrolment patients underwent an AMP provocation
test with doubling concentrations of AMP increasing
from 0.04 mg/ml to 160 mg/ml, inhaled during 2 minutes
tidal breathing at intervals of 5 minutes until a fall from
baseline FEV1 of ≥30% was demonstrated. Hereafter, ICS
and bronchodilator treatment was standardised for the
remainder of the study as once daily (in the evening) two
inhalations of budesonide/formoterol 160/4.5 μg per dose
(160/4.5 μg represents the delivered dose, this is 200/6 μg
Figure 1 Study design of the Test Days.
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Sweden) and with terbutaline 250 μg per dose (Bricanyl®
Turbuhaler®, AstraZeneca, Sweden) for "as needed" use.
At the second visit, and after omitting the previous eve-
ning dose of budesonide/formoterol and abstaining from
terbutaline use for 6 hours, responsiveness to inhaled
AMP was confirmed in an abbreviated AMP provocation
test, giving only the last four AMP doses that were given
at enrolment (this was interrupted if FEV1 decreased
≥30%). Thereafter, on each of the subsequent four test
days, three abbreviated AMP challenges were performed,
commencing at approximately 09:00, at 12:00 and at
16:00 hours.
Test-day assessments
The AMP provocation tests were only performed when
the baseline FEV1 at 09:00 hours differed <15% from the
value at enrolment and when FEV1 prior to each test was
>60% of predicted. At the moment of completing the first
AMP challenge on the test days, thus when there was an
approximate 30% fall in FEV1 and within one minute of
inhaling the last AMP dose, one of the double-blind treat-
ments was inhaled: one inhalation of budesonide/formot-
erol 160/4.5 μg (via Turbuhaler®), one inhalation of
formoterol 4.5 μg (via Turbuhaler®), two inhalations of
salbutamol 100 μg (via pMDI connected to Volumatic), or
placebo. On all occasions one inhalation from Turbu-
haler® and 2 inhalations from the pMDI were inhaled.
Patients were randomised so that half of them used Tur-
buhaler® for their first inhalation on each of the four test
days and half used the pMDI first. Inhalers containing
placebo or active medication had an identical appearance.
The primary (FEV1) and secondary parameters (mean
forced expiratory flow between 25% and 75% of forced
vital capacity [FEF25-75] and the modified Borg scale
[range 0-10] for perceived breathlessness [27]) were mea-
sured during the provocation test and at 1, 3, 5, 10, 15, 30,
45 and 60 minutes after each AMP provocation as well as
hourly in between AMP provocations.
The highest values of three attempts of FEV1 and FEF25-
75 were recorded [28] apart from during the first 20 min-
utes following AMP provocation when single assess-
ments were made. During the abbreviated provocation
itself, the lowest FEV1 (for safety reasons not the highest
value was used) and the highest FEF25-75 of single assess-
ments at 30 and 90 seconds after each 2-minute AMP
inhalation were recorded.
Statistical analysis
The primary aim of the study was to compare the magni-
tude of the bronchoprotective effects of budesonide/for-
moterol in comparison with formoterol alone. This was
assessed as: (1) the maximal % fall in FEV1 in the 16:00
hours AMP provocation; (2) the mean % fall in FEV1 (cal-
culated from the Area Under the FEV1 Curve (AUC0-60)
from 0 to 60 minutes after the 16:00 hours AMP provoca-
tion); (3) the maximal % fall in FEV1 in the 12:00 hours
AMP provocation; and (4) the Area Under the Curve on
the entire Test Day, from 09:00 to 17:00 hours (AUC9-17)
for FEV1. For the secondary parameters FEF25-75 and Borg
Score only the AUC9-17 was calculated and compared.
The % fall in FEV1 in the 12:00 and 16:00 hours provoca-
tion was expressed as % change from the baseline FEV1,
measured immediately prior to that provocation to com-
pensate for remaining bronchodilation from the study
drug or remaining bronchoconstriction from AMP. For
AUC9-17, the FEV1 and FEF25-75 values were expressed as
% change from the test-day baseline value at 09:00 hours,
the Borg score was expressed as absolute changes from
the test-day baseline.
The onset of relief of bronchoconstriction by budes-
onide/formoterol after the first AMP provocation at
09:00 hours was expressed as the increase from the low-
est FEV1 after AMP to the FEV1 at 3 minutes with both
expressed as a % of baseline FEV1.
PC20-AMP values were calculated by interpolation
from a log cumulative concentration versus % decrease in
FEV1 response curve.
The AMP-induced change in FEV1 in the AMP provo-
cation (as the ratio lowest/baseline FEV1) was compared
between treatments in an additive analysis of variance
model with subject, period and treatment as fixed factors
and the test-day baseline FEV1 as covariate. Mean
changes in FEV1 and two-sided 95% confidence intervals
were calculated. Mean treatment differences were esti-
mated by least-squares means resulting from this model.
Other parameters were also analysed in this way. Of the
above mentioned four ways to estimate the bronchopro-
tective effect, one parameter was chosen as the primary
parameter in the power calculation prior to the study and
in the statistical analysis: maximal % fall in the 16:00
hours AMP provocation. For this parameter, all six com-
parisons between the four treatments were tested. For all
other parameters, statistical comparisons were restricted
to the comparisons of budesonide/formoterol versus the
three other treatments.
This study design with three AMP provocations on one
each test day had not been used before. Therefore, sample
size calculation was performed using data from a
repeated cold air and exercise challenge study [29]. With
an assumed standard deviation of 6.8% for the fall in the
third AMP provocation and a power of 80%, a difference
in the % fall in FEV1 of 4.5% would be detectable with 20
patients.
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Patients
Eighteen patients were randomised. One patient was
withdrawn on the first test day prior to study treatment
because of a baseline FEV1 below 85% of the FEV1 at
enrolment, leaving 17 patients who received at least one
dose of the study treatments. As a result of expiry of study
drugs, no additional patients could be enrolled and two
patients had to be withdrawn after completing two or
three test days, respectively. Three test days were post-
poned because of unstable baseline lung function or use
of non-allowed medication. No test day had to be inter-
rupted for administration of bronchodilators. A summary
of demographic and clinical data at enrolment is pre-
sented in Table 1. Baseline FEV1, the actual doses of AMP
given and the resulting decrease in FEV1 and increase in
Borg dyspnoea score prior to study treatment inhalation
were very similar on each of the four test days (Table 2).
Bronchoprotective effects
For the primary endpoint, the mean maximal fall after the
third AMP provocation performed at 16:00 hours (i.e. 7
hours after treatment), was 15.7% after budesonide/for-
moterol, numerically (but not significantly) less than the
20.1% fall after formoterol (p = 0.24) and significantly less
than the 29.8% and 31.9% fall after salbutamol (p =
0.0005) and placebo (p < 0.0001), respectively (Table 3).
Formoterol alone provided significantly more protection
(smaller fall in FEV1) than salbutamol (p = 0.014) and pla-
cebo (p = 0.0025) but salbutamol did not do better than
placebo at 7 hours (p = 0.57).
The mean fall in FEV1 in the 60 minutes after the 16:00
hours AMP challenge (AUC0-60) was significantly smaller
following budesonide/formoterol pre-treatment than that
after formoterol (p = 0.045), salbutamol (p = 0.0001) and
placebo (p < 0.0001) (Table 3).
All active treatments attenuated the bronchoconstric-
tion by the AMP challenge at 3 hours after inhalation (i.e.
12:00 hours). The maximal % fall in FEV1 following
budesonide/formoterol (8.8%) was significantly lower
than that after formoterol (17.0%, p = 0.023), salbutamol
(20.1%, p = 0.0028) and placebo (27.1%, p < 0.0001) (Table
3).
Profile of FEV1, FEF25-75 and Borg score over the day
The time course of FEV1 over the entire test day is pre-
sented in Figure 2. Initially, FEV1 was highest following 2
inhalations of salbutamol, but from 2 hours after inhala-
tion onwards, FEV1 was highest following budesonide/
formoterol. When calculated over the entire test day (as
FEV1 AUC9-17), the FEV1 after budesonide/formoterol
was significantly greater than that after formoterol (p =
0.033), salbutamol (p = 0.0011) and placebo (p < 0.0001,
Table 4).
The time course of FEF25-75 over the test day is shown
in Figure 3. From 45 minutes onwards, FEF25-75 was
highest following budesonide/formoterol. The FEF25-75
AUC9-17 for budesonide/formoterol tended to be greater
than that after formoterol (p = 0.070), and differed signif-
icantly from that after salbutamol (p = 0.0005) and pla-
cebo (p < 0.0001).
The time course of Borg dyspnoea score over the test
day is shown in Figure 4. Dyspnoea recovered quickly fol-
lowing all three active treatments. In the third AMP prov-
ocation salbutamol had lost its protective effect as
assessed with the subjective Borg score whereas both for-
moterol and budesonide/formoterol had a residual pro-
tective effect against AMP-induced dyspnoea. The Borg
score AUC9-17 after budesonide/formoterol was, however,
not significantly different compared with formoterol (p =
0.57) or salbutamol (p = 0.37) but differed significantly
from placebo (p = 0.0039).
Immediate bronchodilating effect
All three active treatments rapidly reversed the AMP-
induced bronchoconstriction at 09:00 hours. At 3 min-
utes after inhalation, the single dose of budesonide/for-
moterol induced an increase in FEV1 of 15.2%, which was
statistically significant larger than the 1.7% increase
observed after placebo (p < 0.0001), and was comparable
to the increase observed with formoterol (13.2%, p = 0.44)
but smaller than the 21.5% increase seen after two doses
of salbutamol (p = 0.023).
Table 1: Patient baseline demographics
Characteristic Value
Sex: Male/Female, n 6/11
Mean age, years (range) 37.2 (20-53)
Median time since asthma 
diagnosis, years (range)
20.2 (3-42)
Mean inhaled corticosteroid 
dose prior to the study, μg 
(range)
553 (200-800)
User of long-acting β2-
agonist prior to the study
14
Mean FEV1, L (range) 3.26 (2.11-4.69)
Mean FEV1, % predicted 
(range)
94.6 (63-126)
Geometric mean PC20-AMP, 
mg/ml (range)
2.64 (0.08-125)
FEV1: forced expiratory volume in 1 second; PC20: provocative 
concentration of adenosine 5'-monophoshate (AMP) causing a 
20% fall in FEV1.
Aalbers et al. Respiratory Research 2010, 11:66
http://respiratory-research.com/content/11/1/66
Page 5 of 9Discussion
Overall, a single low dose of the combination budes-
onide/formoterol (160/4.5 μg) had a greater protective
effect at 3 and 7 hours after inhalation than a single dose
of formoterol 4.5 μg alone, although the difference
between these two treatments did not meet the pre-
defined primary endpoint of the maximum % fall in FEV1
7 hours after the first AMP challenge. As expected, both
treatments with formoterol showed a superior duration
of protection relative to the reference treatment salbuta-
mol, which has a shorter half-life of action. These data
also support an immediate and lasting additive effect of
the inhaled corticosteroid budesonide in protecting
against an indirect airway stimulus in asthmatics and
provide further rationale for the use of the combination
on an as needed basis to prevent further deterioration in
case of an asthma exacerbation.
Our study is the first to substantiate the magnitude and
duration of the additive protective effect against AMP-
induced bronchoconstriction of a low dose of an inhaled
corticosteroid on top of a long-acting bronchodilator.
Our data add to and are consistent with the previous
observation that a single dose of the inhaled corticoster-
oid fluticasone protects against AMP-induced bronchoc-
onstriction [25,26], and that the effect of a high dose lasts
for at least several hours [26]. In a recent study, the
budesonide/formoterol combination given immediately
after allergen provocation also proved superior to both
single components in preventing the late asthmatic reac-
tion as well as the associated increase in bronchial hyper-
responsiveness [30].
The study design was intended to mimic an acute
asthma exacerbation with multiple AMP provocation
tests on single test days. This gave us a unique opportu-
nity to test the contribution of different inhaled drugs,
acting via different mechanisms, in this situation. As with
every model it has its limitations and does not fully repre-
sent a real life asthma attack. Furthermore, because exac-
erbations can be precipitated by different exposures such
as viral infection or allergen exposure, different mecha-
nisms may be involved. In addition, the study was proba-
bly slightly underpowered as the sample size estimation
was 20, but only 17 patients received treatment and of
those only 15 patients had full data available. The additive
effect of budesonide on the primary endpoint % fall in
FEV1 at 7 hours was close to the smallest detectable dif-
ference according to the pre-study power calculation
(4.4% vs. 4.5% fall) but the standard deviation in the % fall
was larger than assumed (10.6% versus 6.8%). On the
other hand, for all 3 predefined secondary endpoints with
Table 2: Adenosine 5'-monophosphate provocation test data at 09:00 hours, immediately before administration of study 
treatments
Treatment Baseline FEV1, before 
provocation (L)
AMP dose (mg/ml) Fall in FEV1 after AMP 
provocation (%)
Increase in Borg 




3.13 (0.80) 109 (184) 28.0 (14.0) 2.50 (1.40)
Formoterol 3.11 (0.86) 122 (193) 28.7 (12.2) 2.00 (1.35)
Salbutamol 3.03 (0.91) 110 (191) 31.6 (14.5) 2.91 (1.58)
Placebo 3.06 (0.89) 106 (186) 29.4 (10.6) 2.79 (1.57)
All data are presented as mean (SD); FEV1: forced expiratory volume in 1 second; AMP: adenosine 5'-monophoshate; AMP dose as cumulative 
nebulized concentration.
Table 3: Protective effects of study treatments in repeated AMP provocations
Fall in FEV1 in AMP provoca-
tion at 3 hours (%)
Fall in FEV1 in AMP provoca-
tion at 7 hours (%)
AUC0-60-FEV1 in AMP 
provocation at 7 hours (h.%)
Budesonide/formoterol 8.8 (4.0, 13.6) 15.7 (10.7, 20.8) -4.2 (- 8.6, 0.2)
Formoterol 17.0 (11.8, 22.1)* 20.1 (14.6, 25.5) -10.7 (- 15.4, -6.0)*
Salbutamol 20.1 (15.0, 25.2)# 29.8 (24.4, 35.2)$ -17.9 (- 22.5, -13.2)$
Placebo 27.1 (22.3, 31.8)$ 31.9 (26.9, 36.9)$ -19.9 (- 24.3, -15.6)$
Data shown as Least Square Mean and 95% Confidence Interval; FEV1: forced expiratory volume in 1 second; AMP: adenosine 5'-
monophoshate; fall in FEV1 as % from baseline prior to each AMP provocation; AUC0-60: Area Under the Curve for % change in FEV1 from 0 to 
60 minutes after AMP provocation; p-values from ANOVA, differences compared with budesonide/formoterol: *p < 0.05, #p < 0.01, $p < 0.001.
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tically significant.
Ideally, the study would have had an additional study
limb in which only budesonide would have been given.
This was considered too large a burden for the patients.
Additionally, it would not have added to answer our
research question on the additive bronchoprotective
effect of budesonide on top of the well established effect
of formoterol as relief medication.
To explain the observed additive protective effects of
budesonide over those of formoterol alone, the potential
immediate effects of a corticosteroid on the postulated
mechanisms of AMP-induced airway narrowing need to
be considered. AMP induces mast cell degranulation and
release of mediators leading to airway narrowing due to
smooth muscle constriction and mucosal edema as a
result of increased mucosal blood flow and increased
microvascular permeability [20]. AMP might also act on
adenosine receptors in vascular beds and neurosecretory
cells to induce mucosal edema directly. Because there is
no evidence that a single inhalation of a corticosteroid
reduces mast cell number or function, inhibition of mast







Budesonide/formoterol 20.9 (3.7, 38.1) 134 (69.8, 198) 0.21 (-1.64, 2.07)
Formoterol -6.4 (-25.0, 12.1)* 47.8 (-21.5, 117) -0.55 (-2.55, 1.45)
Salbutamol -23.6 (-41.9, -5.3)$ -44.6 (-113, 23.8)# 1.47 (-0.50, 3.45)
Placebo -61.0 (-77.9, -44.0)$ -66.2(-130, 2.8)$ 4.20 (2.37, 6.03) $
Data shown as Geometric Mean and 95% confidence interval; AUC9-17: Area Under the Curve from 09:00 to 17:00 hours, covering three AMP 
provocations; changes relative to test-day baseline at 09:00 hours; FEV1: forced expiratory volume in 1 second; FEF25-75: forced expiratory flow 
between 25% and 75% of forced vital capacity; comparisons by ANOVA, differences compared to budesonide/formoterol: *p < 0.05, #p < 0.01, 
$p < 0.001.
Figure 2 Mean FEV1 over the test day with three AMP provocations followed by a single dose of budesonide/formoterol 160/4.5 μg (open 
diamonds), formoterol 4.5 μg (open squares), salbutamol 2 × 100 μg (filled triangles) or placebo (crosses) immediately after the first AMP 
provocation.
Aalbers et al. Respiratory Research 2010, 11:66
http://respiratory-research.com/content/11/1/66
Page 7 of 9cell mediator responses is a more likely explanation. In a
rat study airway microvascular permeability was shown
to be inhibited within several hours after single-dose cor-
ticosteroid administration [31]. In addition ICS induce a
rapid vasoconstriction by non-genomic effects in asth-
matic airways [32,33]. Apparently, these immediate
effects of an inhaled corticosteroid on the airway vascular
bed provide additional protective benefit over the func-
tional antagonism by formoterol against airway smooth
muscle contraction.
Although the latter may be considered a rationale for
combining budesonide and formoterol in a single inhaler
to be used also for acute asthma symptoms, the clinical
relevance might be questioned since the differences
between budesonide/formoterol and single formoterol in
Borg dyspnoea score over the entire test day were not sta-
tistically significant. However, this is most likely because
the Borg scores rapidly returned to symptom-free base-
line values in between AMP provocations, leaving little
room for further improvement. It can be hypothesized
that immediate bronchoprotection via multiple mecha-
nisms early during an imminent asthma attack may ame-
liorate symptoms to such an extent that a full-blown
asthma exacerbation is prevented. Support for this can be
found in the results of clinical trials that have shown
reduced exacerbation rates following use of budesonide/
formoterol as maintenance and reliever therapy [10-14]
and the efficacy of the combination in the emergency set-
ting [34,35].
In conclusion, the budesonide within the budesonide/
formoterol combination inhaler provides additional and
sustained protective effects against the external stimulus
inhaled AMP in comparison with formoterol alone. In
addition, the budesonide/formoterol combination pro-
vides immediate bronchodilation when inhaled in a state
of bronchoconstriction. This supports the use of this
combination for both relief and prevention of asthma
symptoms.
Figure 3 Mean FEF25-75 over the Test Day with three AMP provocations followed by a single dose of budesonide/formoterol 160/4.5 μg 
(open diamonds), formoterol 4.5 μg (open squares), salbutamol 2 × 100 μg (filled triangles) or placebo (crosses) immediately after the first 
AMP provocation.
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AMP: adenosine 5'-monophosphate; AUC0-60: Area Under the Curve for the 60
minutes after the provocation at 16:00 hours; AUC9-17: Area Under the Curve
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Figure 4 Mean Borg score over the Test Day with three AMP provocations followed by a single dose of budesonide/formoterol 160/4.5 μg 
(open diamonds), formoterol 4.5 μg (open squares), salbutamol 2 × 100 μg (filled triangles) or placebo (crosses) immediately after the first 
AMP provocation.
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